ETON · Eton Pharmaceuticals, Inc.
AI read · Neutral
The AI's read
Eton reported Q2 revenue of $37.6M, up 99% YoY, and raised 2026 revenue guidance above $145M with adjusted EBITDA margin expected >35%. That’s a clear operational beat driven by Hemangiol’s relaunch and new portfolio add-ons. The stock already jumped ~17% on the news and RSI is 76, so a lot of momentum is priced in. That compresses immediate upside despite the legitimately stronger fundamentals. We lean bullish on the story because growth and margins just improved materially, but we’re cautious on entry given valuation and momentum. Prefer watching for a pullback or consolidation before adding exposure in size.